Tirzepatide emerges a groundbreaking treatment agent for individuals battling type 2 diabetes. As a dual receptor activator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, leading synergistic effects on blood sugar control. By augmenting insulin secretion and reducing glucagon r